Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder
Francisco Moreno, Christopher B. Wiegand, E. Keolani Taitano, Pedro L. Delgado
The Journal of Clinical Psychiatry November 15, 2006 DOI: 10.4088/jcp.v67n1110 (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractIn a controlled clinical setting, psilocybin was safely administered to individuals with obsessive-compulsive disorder (OCD) and was linked to immediate decreases in core OCD symptoms in several participants.
Study at a glance
| Characteristics | Controlled clinical trial Peer reviewed |
|---|---|
| Population | Subjects with obsessive-compulsive disorder (OCD) |
| Intervention | Psilocybin |
| Topics | Anxiety Psilocybin |
| Keywords | Tolerability Hallucinogen Adverse effect Obsessive compulsive |
| Citations | 786 |
| Key finding | Psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects. |
Abstract
In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.